EMA says the eXtended EudraVigilance Medicinal Product Dictionary, or XEVMPD, supports pharmacovigilance activities in the EU, and it continues to publish 2026 training dates for the system. EMA’s registration guidance also says organisations need notification of successful XEVMPD knowledge evaluation for at least one user in relevant registration contexts.
That is an important career signal. Modern PV work is not only about adverse-event data; it also depends on accurate product-data structures, controlled submissions, and the ability to work across linked regulatory systems. XEVMPD may sit more quietly in the background than signal detection or AI, but it still underpins real regulatory operations. This is an inference from EMA’s continuing training and registration framework.
For professionals who want to stand out, product-data literacy remains an underrated asset. Sometimes the most valuable skills are the ones the system quietly depends on.
0 Comments